IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v18y2017i1d10.1007_s10198-015-0757-y.html
   My bibliography  Save this article

Economic burden of toxicities associated with treating metastatic melanoma in eight countries

Author

Listed:
  • Elizabeth Wehler

    (IMS Health)

  • Zhongyun Zhao

    (Amgen)

  • S. Pinar Bilir

    (IMS Health)

  • Julie Munakata

    (IMS Health)

  • Beth Barber

    (Amgen)

Abstract

Background Information on costs of managing adverse events (AEs) associated with current treatments in metastatic melanoma is limited. This study estimates costs of AEs in eight countries: Australia (AU), Canada (CA), France (FR), Germany (GE), Italy (IT), the Netherlands (NL), Spain (ES), and the UK. Methods A literature search was conducted to identify grade 3/4 AEs from product label, published trials, conference abstracts, and treatment guidelines. Resource utilization for the management of each type of AE was determined via interviews with 5 melanoma clinicians in each country. Outpatient and inpatient costs were estimated for each type of AE using country-specific tariffs or government/published sources. Results In outpatient settings, the most costly AEs per incident included cutaneous squamous cell carcinoma (CSCC) (€1063, £720; NL/UK), anemia (€1443, €1329, €1285; ES/IT/FR), peripheral neuropathy (€1289; ES), and immune-related diarrhea (AUS$1,121; AU). In inpatient settings, the most costly AEs per hospitalization included hypophysitis (€10,265; €5316; CAN$9735; AUS$7231: ES/FR/CA/AU), dyspnea (€9077; GE), elevated liver enzymes (€6913, CAN$8030, AUS$6594; FR/CA/AU), CSCC (CAN$8934; CA), peripheral neuropathy (€6977, €4144, CAN$9472; NL/ES/CA), and diarrhea (£4284, €4113; UK/ES). Conclusions Costs of managing AEs can be significant, and thus effective treatments with lower rates of severe AEs would be valuable.

Suggested Citation

  • Elizabeth Wehler & Zhongyun Zhao & S. Pinar Bilir & Julie Munakata & Beth Barber, 2017. "Economic burden of toxicities associated with treating metastatic melanoma in eight countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(1), pages 49-58, January.
    • Handle: RePEc:spr:eujhec:v:18:y:2017:i:1:d:10.1007_s10198-015-0757-y
    DOI: 10.1007/s10198-015-0757-y
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-015-0757-y
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-015-0757-y?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Lotte Westerink & Jelmer L. J. Nicolai & Carl Samuelsen & Hans J. M. Smit & Pieter E. Postmus & Ingolf Griebsch & Maarten J. Postma, 2020. "Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(6), pages 931-943, August.
    2. Marine Sivignon & Rémi Monnier & Bertrand Tehard & Stéphane Roze, 2020. "Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France," PLOS ONE, Public Library of Science, vol. 15(1), pages 1-14, January.

    More about this item

    Keywords

    Adverse drug event; Melanoma; Costs and cost analysis; Cost of illness;
    All these keywords.

    JEL classification:

    • L19 - Industrial Organization - - Market Structure, Firm Strategy, and Market Performance - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:18:y:2017:i:1:d:10.1007_s10198-015-0757-y. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.